Meridian Bioscience (VIVO) Reports Q4 EPS of $0.19, Offers FY21 Guidance
Get Alerts VIVO Hot Sheet
Price: $33.97 --0%
Revenue Growth %: -100.0%
Financial Fact:
OPERATING INCOME: 8.9M
Today's EPS Names:
SEIC, OSBC, USAP, More
Revenue Growth %: -100.0%
Financial Fact:
OPERATING INCOME: 8.9M
Today's EPS Names:
SEIC, OSBC, USAP, More
Join SI Premium – FREE
Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.19, versus $0.14 consensus. Revenue for the quarter came in at $64.2 million, versus $59.6 million consensus.
GUIDANCE:
Meridian Bioscience sees FY2021 EPS of $1.14-$1.28, versus the consensus of $1.02. Meridian Bioscience sees FY2021 revenue of $290-310 million, versus the consensus of $249.15 million.
For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Visa (V) stock rises as Q2 earnings, revenue come ahead of estimates
- Veralto Corporation (VLTO) Tops Q1 EPS by 6c, Offers Guidance
- New Oriental Education (EDU) Misses Q1 EPS by 12c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!